• 1
    Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 (Suppl 4), 3139.
  • 2
    Salomon DS, Brandt R, Ciardiello F & Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19, 183232.
  • 3
    Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH & Bigner DD (1990) Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 87, 42074211.
  • 4
    Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK & Huang HJ (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91, 77277731.
  • 5
    Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ et al. (2003) A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 100, 639644.
  • 6
    Voldborg BR, Damstrup L, Spang-Thomsen M & Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8, 11971206.
  • 7
    Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN & Reist CJ (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55, 31403148.
  • 8
    Yamazaki H, Ohba Y, Tamaoki N & Shibuya M (1990) A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn J Cancer Res 81, 773779.
  • 9
    Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD & Bigner SH (1988) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48, 22312238.
  • 10
    Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS & Bigner DD (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6, 12511259.
  • 11
    Downward J, Parker P & Waterfield MD (1984) Autophosphorylation sites on the epidermal growth factor receptor. Nature 311, 483485.
  • 12
    Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD & Pastan I (1995) Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res 1, 859864.
  • 13
    Montgomery RB, Moscatello DK, Wong AJ, Cooper JA & Stahl WL (1995) Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 270, 3056230566.
  • 14
    Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD & Zalutsky MR (1995) Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55, 43754382.
  • 15
    Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD & Pastan I (1996) Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 93, 1481514820.
  • 16
    Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY & Wong AJ (1996) Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13, 8596.
  • 17
    Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS & Cavenee WK (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272, 29272935.
  • 18
    Montgomery RB, Moscatello DK, Wong AJ & Stahl WL (1997) Epidermal growth factor receptor stimulation of diacylglycerol kinase. Biochem Biophys Res Commun 232, 111116.
  • 19
    Reist CJ, Batra SK, Pegram CN, Bigner DD & Zalutsky MR (1997) In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nucl Med Biol 24, 639647.
  • 20
    Antonyak MA, Moscatello DK & Wong AJ (1998) Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem 273, 28172822.
  • 21
    Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB & Wong AJ (1998) Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273, 200206.
  • 22
    Nagane M, Levitzki A, Gazit A, Cavenee WK & Huang HJ (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95, 57245729.
  • 23
    Feldkamp MM, Lau N & Guha A (1999) Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 18, 75147526.
  • 24
    Feldkamp MM, Lau N, Rak J, Kerbel RS & Guha A (1999) Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer 81, 118124.
  • 25
    Kuan CT, Wikstrand CJ, Archer G, Beers R, Pastan I, Zalutsky MR & Bigner DD (2000) Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer 88, 962969.
  • 26
    Montgomery RB, Guzman J, O'Rourke DM & Stahl WL (2000) Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 275, 1735817363.
  • 27
    Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH et al. (2000) Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 97, 75037508.
  • 28
    Tang CK, Gong XQ, Moscatello DK, Wong AJ & Lippman ME (2000) Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 60, 30813087.
  • 29
    Fernandes H, Cohen S & Bishayee S (2001) Glycosylation-induced conformational modification positively regulates receptor–receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. J Biol Chem 276, 53755383.
  • 30
    Foulon CF, Welsh PC, Bigner DD & Zalutsky MR (2001) Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. Nucl Med Biol 28, 769777.
  • 31
    Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW & Scott AM (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61, 53555361.
  • 32
    Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ et al. (2001) Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61, 53495354.
  • 33
    Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK & Huang HJ (2001) Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95, 472479.
  • 34
    Pedersen MW, Thykjaer T, Orntoft TF, Damstrup L & Poulsen HS (2001) Profile of differentially expressed genes mediated by the type III epidermal growth factor receptor mutation expressed in a small-cell lung cancer cell line. Br J Cancer 85, 12111218.
  • 35
    Damstrup L, Wandahl Pedersen M, Bastholm L, Elling F & Skovgaard Poulsen H (2002) Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int J Cancer 97, 714.
  • 36
    Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD & Sampson JH (2002) Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50, 158164; discussion 164–166.
  • 37
    Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD et al. (2002) Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res 8, 34963502.
  • 38
    Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC et al. (2002) Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 98, 398408.
  • 39
    Montgomery RB (2002) Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function. Int J Cancer 101, 111117.
  • 40
    Vaidyanathan G, Affleck DJ, Bigner DD & Zalutsky MR (2002) Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl Med Biol 29, 111.
  • 41
    Wikstrand CJ, Cole VR, Crotty LE, Sampson JH & Bigner DD (2002) Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol Immunother 50, 639652.
  • 42
    Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ et al. (2003) Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100, 1587115876.
  • 43
    Lammering G, Hewit TH, Valerie K, Contessa JN, Amorino GP, Dent P & Schmidt-Ullrich RK (2003) EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene 22, 55455553.
  • 44
    Luo X, Gong X & Tang CK (2003) Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme. Int J Cancer 104, 716721.
  • 45
    Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD & Park JW (2003) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 63, 31543161.
  • 46
    Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean C, Thomas H et al. (2003) Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR mAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 105, 273280.
  • 47
    Takasu S, Takahashi T, Okamoto S, Oriuchi N, Nakayashiki N, Okamoto K, Muramatsu H, Hayashi T, Nakahara N, Mizuno M et al. (2003) Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99 m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. J Neurooncol 63, 247256.
  • 48
    Abulrob A, Giuseppin S, Andrade M, McDermid A, Moreno M & Stanimirovic D (2004) Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 23, 69676979.
  • 49
    Lammering G, Valerie K, Lin P-S, Hewit TH & Schmidt-Ullrich RK (2004) Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 72, 267273.
  • 50
    Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD & Sampson JH (2004) Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10, 32163224.
  • 51
    Li B, Yuan M, Kim IA, Chang CM, Bernhard EJ & Shu HK (2004) Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 23, 45944602.
  • 52
    Luwor RB, Zhu HJ, Walker F, Vitali AA, Perera RM, Burgess AW, Scott AM & Johns TG (2004) The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cell survival and heterodimerizes with the wild-type EGFR. Oncogene 23, 60956104.
  • 53
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J et al. (2004) AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64, 49314941.
  • 54
    Wu G, Barth RF, Yang W, Chatterjee M, Tjarks W, Ciesielski MJ & Fenstermaker RA (2004) Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug Chem 15, 185194.
  • 55
    Cai XM, Tao BB, Wang LY, Liang YL, Jin JW, Yang Y, Hu YL & Zha XL (2005) Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression. Int J Cancer 117, 905912.
  • 56
    Johns TG, Mellman I, Cartwright GA, Ritter G, Old LJ, Burgess AW & Scott AM (2005) The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J 19, 780782.
  • 57
    Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB & Park JW (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65, 1163111638.
  • 58
    Ning Y, Zeineldin R, Liu Y, Rosenberg M, Stack MS & Hudson LG (2005) Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res 65, 92809286.
  • 59
    Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D et al. (2005) Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer 92, 10691077.
  • 60
    Pedersen MW, Pedersen N, Damstrup L, Villingshoj M, Sonder SU, Rieneck K, Bovin LF, Spang-Thomsen M & Poulsen HS (2005) Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation. J Cell Biochem 96, 412427.
  • 61
    Pedersen MW, Pedersen N, Ottesen LH & Poulsen HS (2005) Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer 93, 915923.
  • 62
    Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA et al. (2005) Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11, 63906399.
  • 63
    Yang W, Barth R, Wu G, Ciesielski M, Fenstermaker R, Moffat B, Ross B & Wikstrand C (2005) Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res 11, 341350.
  • 64
    Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM et al. (2006) Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 66, 1184011850.
  • 65
    Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg PV & Lenz HJ (2006) Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer 6, 214218.
  • 66
    Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L et al. (2006) Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 12, 46714677.
  • 67
    Davies GC, Ryan PE, Rahman L, Zajac-Kaye M & Lipkowitz S (2006) EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins. Oncogene 25, 64976509.
  • 68
    Han W, Zhang T, Yu H, Foulke JG & Tang CK (2006) Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther 5, 13611368.
  • 69
    Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T, Maxwell D, Soghomonyan S, Shavrin A, Ageyeva L et al. (2006) Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 8, 262277.
  • 70
    Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET et al. (2006) Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 66, 867874.
  • 71
    Shankar S, Vaidyanathan G, Kuan CT, Bigner DD & Zalutsky MR (2006) Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nucl Med Biol 33, 101110.
  • 72
    Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD et al. (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12, 50645073.
  • 73
    Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ et al. (2006) Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res 12, 37923802.
  • 74
    Zeineldin R, Rosenberg M, Ortega D, Buhr C, Chavez MG, Stack MS, Kusewitt DF & Hudson LG (2006) Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III. Mol Carcinog 45, 851860.
  • 75
    Aerts HJ, Dubois L, Hackeng TM, Straathof R, Chiu RK, Lieuwes NG, Jutten B, Weppler SA, Lammering G, Wouters BG et al. (2007) Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiother Oncol 83, 326332.
  • 76
    Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM & Furnari FB (2007) The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 13, 19111925.
  • 77
    Larsen AB, Pedersen MW, Stockhausen M-T, Grandal MV, Deurs BV & Poulsen HS (2007) Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 5, 283293.
  • 78
    Patel D, Lahiji A, Patel S, Franklin M, Jimenez X, Hicklin D & Kang X (2007) Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res 27, 33553366.
  • 79
    Weppler SA, Li Y, Dubois L, Lieuwes N, Jutten B, Lambin P, Wouters BG & Lammering G (2007) Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol 83, 333339.
  • 80
    Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A & Rak J (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10, 619624.
  • 81
    Cemeus C, Zhao TT, Barrett GM, Lorimer IA & Dimitroulakos J (2008) Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol 90, 917.
  • 82
    de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, Depinho RA & Bonni A (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22, 449462.
  • 83
    Du W, Xu Z, Nystrom AM, Zhang K, Leonard JR & Wooley KL (2008) 19F- and fluorescently labeled micelles as nanoscopic assemblies for chemotherapeutic delivery. Bioconjug Chem 19, 24922498.
  • 84
    Fromm JA, Johnson SA & Johnson DL (2008) Epidermal growth factor receptor 1 (EGFR1) and its variant EGFRvIII regulate TATA-binding protein expression through distinct pathways. Mol Cell Biol 28, 64836495.
  • 85
    Fukai J, Nishio K, Itakura T & Koizumi F (2008) Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci 99, 20622069.
  • 86
    Kim K, Brush JM, Watson PA, Cacalano NA, Iwamoto KS & McBride WH (2008) Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation. Mol Cancer Res 6, 426434.
  • 87
    Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ et al. (2008) A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14, 57595768.
  • 88
    Lo HW, Cao X, Zhu H & Ali-Osman F (2008) Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 14, 60426054.
  • 89
    Ochiai H, Archer GE, Herndon JE II, Kuan CT, Mitchell DA, Bigner DD, Pastan IH & Sampson JH (2008) EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunol Immunother 57, 115121.
  • 90
    Stutz MA, Shattuck DL, Laederich MB, Carraway KL III & Sweeney C (2008) LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 27, 57415752.
  • 91
    Wang S, Guo P, Wang X, Zhou Q & Gallo JM (2008) Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther 7, 407417.
  • 92
    Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, Kratzke RA, Dudek A, Potter DA, Woo RA, O'Rourke DM et al. (2008) Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther 7, 35863597.
  • 93
    Yang W, Wu G, Barth RF, Swindall MR, Bandyopadhyaya AK, Tjarks W, Tordoff K, Moeschberger M, Sferra TJ, Binns PJ et al. (2008) Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res 14, 883891.
  • 94
    Andersen P, Villingshoj M, Poulsen HS & Stockhausen MT (2009) Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells. Cancer Invest 27, 178183.
  • 95
    Bullain SS, Sahin A, Szentirmai O, Sanchez C, Lin N, Baratta E, Waterman P, Weissleder R, Mulligan RC & Carter BS (2009) Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol 94, 373382.
  • 96
    Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF & Valerie K (2009) Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8, 730738.
  • 97
    Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M et al. (2009) The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 106, 1293212937.
  • 98
    He M & Young CY (2009) Mutant epidermal growth factor receptor vIII increases cell motility and clonogenecity in a prostate cell line RWPE1. J Endocrinol Invest 32, 272278.
  • 99
    Hens M, Vaidyanathan G, Welsh P & Zalutsky MR (2009) Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. Nucl Med Biol 36, 117128.
  • 100
    Joughin BA, Naegle KM, Huang PH, Yaffe MB, Lauffenburger DA & White FM (2009) An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. Mol BioSyst 5, 5967.
  • 101
    Kaur B, Cork SM, Sandberg EM, Devi NS, Zhang Z, Klenotic PA, Febbraio M, Shim H, Mao H, Tucker-Burden C et al. (2009) Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 69, 12121220.
  • 102
    Li L, Dutra A, Pak E, Labrie JE III, Gerstein RM, Pandolfi PP, Recht LD & Ross AH (2009) EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol 11, 921.
  • 103
    Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I et al. (2009) Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res 69, 68896898.
  • 104
    Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B, Madden C, Maher E et al. (2009) EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69, 42524259.
  • 105
    Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C et al. (2009) Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16, 256265.
  • 106
    Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM & Johns TG (2009) The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11, 448458.
  • 107
    Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N & Brat DJ (2009) Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 69, 25402549.
  • 108
    Wang H, Jiang H, Zhou M, Xu Z, Liu S, Shi B, Yao X, Yao M, Gu J & Li Z (2009) Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. Cancer Lett 279, 3038.
  • 109
    Wang S, Zhou Q & Gallo JM (2009) Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther 8, 14381447.
  • 110
    Yang W, Barth RF, Wu G, Tjarks W, Binns P & Riley K (2009) Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl Radiat Isot 67, S328S331.
  • 111
    Zhan Y, Counelis GJ & O'Rourke DM (2009) The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp Cell Res 315, 23432357.
  • 112
    Zhang Y, Su H, Rahimi M, Tochihara R & Tang C (2009) EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer 125, 20212028.
  • 113
    Vogel TW, Zhuang Z, Li J, Okamoto H, Furuta M, Lee Y-S, Zeng W, Oldfield EH, Vortmeyer AO & Weil RJ (2005) Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res 11, 36243632.
  • 114
    Rae JM, Scheys JO, Clark KM, Chadwick RB, Kiefer MC & Lippman ME (2004) EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat 87, 8795.
  • 115
    Ge H, Gong X & Tang CK (2002) Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 98, 357361.
  • 116
    Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS & Bigner DD (1990) Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50, 80178022.
  • 117
    Pandita A, Aldape KD, Zadeh G, Guha A & James CD (2004) Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosom Cancer 39, 2936.
  • 118
    Martens T, Laabs Y, Gunther HS, Kemming D, Zhu Z, Witte L, Hagel C, Westphal M & Lamszus K (2008) Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res 14, 54475458.
  • 119
    Rieske P, Golanska E, Zakrzewska M, Piaskowski S, Hulas-Bigoszewska K, Wolanczyk M, Szybka M, Witusik-Perkowska M, Jaskolski DJ, Zakrzewski K et al. (2009) Arrested neural and advanced mesenchymal differentiation of glioblastoma cells – comparative study with neural progenitors. BMC Cancer 9, 54.
  • 120
    Witusik-Perkowska M, Rieske P, Hulas-Bigoszewska K, Zakrzewska M, Stawski R, Kulczycka-Wojdala D, Bienkowski M, Stoczynska-Fidelus E, Gresner SM, Piaskowski S et al. (2011) Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies. J Neurooncol 102, 395407.
  • 121
    Schulte A, Gunther HS, Martens T, Zapf S, Riethdorf S, Wulfing C, Stoupiec M, Westphal M & Lamszus K (2012) Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Clin Cancer Res 18, 19011913.
  • 122
    Foulon CF, Reist CJ, Bigner DD & Zalutsky MR (2000) Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res 60, 44534460.
  • 123
    Hills D, Rowlinson-Busza G & Gullick WJ (1995) Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 63, 537543.
  • 124
    Okamoto S, Yoshikawa K, Obata Y, Shibuya M, Aoki S, Yoshida J & Takahashi T (1996) Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. Br J Cancer 73, 13661372.
  • 125
    Ohman L, Gedda L, Hesselager G, Larsson R, Nister M, Stigbrand T, Wester K & Carlsson J (2002) A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumour Biol 23, 6169.
  • 126
    Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N et al. (2008) Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 14, 488493.
  • 127
    Ou C, Wu FX, Luo Y, Cao J, Zhao YN, Yuan WP, Li Y & Su JJ (2005) Expression and significance of epidermal growth factor receptor variant type III in hepatocellular carcinoma. Ai Zheng 24, 166169.
  • 128
    Nieto Y, Nawaz F, Jones RB, Shpall EJ & Nawaz S (2007) Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 25, 44054413.
  • 129
    Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB & James CD (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63, 700707.
  • 130
    Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, Guegan Y & Quillien V (2007) Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81, 139148.
  • 131
    Feldkamp MM, Lala P, Lau N, Roncari L & Guha A (1999) Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45, 14421453.
  • 132
    Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA et al. (2006) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 103, 78177822.
  • 133
    Arjona D, Bello MJ, Alonso ME, Aminoso C, Isla A, De Campos JM, Sarasa JL, Gutierrez M, Villalobo A & Rey JA (2005) Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations. Neuropathol Appl Neurobiol 31, 384394.
  • 134
    Biernat W, Huang H, Yokoo H, Kleihues P & Ohgaki H (2004) Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 14, 131136.
  • 135
    Ekstrand AJ, Sugawa N, James CD & Collins VP (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89, 43094313.
  • 136
    Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, Bigner DD & Weiner LM (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53, 32173220.
  • 137
    Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R & Aldape K (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11, 14621466.
  • 138
    Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL & Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55, 55365539.
  • 139
    Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR, Wong AJ & Habib FK (2000) Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82, 186194.
  • 140
    Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J-I et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63, 69626970.
  • 141
    Sugawa N, Ekstrand AJ, James CD & Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87, 86028606.
  • 142
    Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS & Vogelstein B (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89, 29652969.
  • 143
    Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, Taniguchi S & Shibuya M (1988) Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 8, 18161820.
  • 144
    Sonnweber B, Dlaska M, Skvortsov S, Dirnhofer S, Schmid T & Hilbe W (2006) High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J Clin Pathol 59, 255259.
  • 145
    Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F, Jones C & Reis RM (2008) Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res 28, 913920.
  • 146
    Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK & Huang HJ (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56, 50795086.
  • 147
    Patel TB (2004) Single transmembrane spanning heterotrimeric g protein-coupled receptors and their signaling cascades. Pharmacol Rev 56, 371385.
  • 148
    Reardon DA & Wen PY (2006) Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11, 152164.
  • 149
    Gan HK, Kaye AH & Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16, 748754.
  • 150
    Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF & Collins VP (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51, 21642172.
  • 151
    Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A & Schlessinger J (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144147.
  • 152
    Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353, 20122024.
  • 153
    Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD et al. (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93, 12461256.
  • 154
    Frederick L, Wang XY, Eley G & James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60, 13831387.
  • 155
    Malden LT, Novak U, Kaye AH & Burgess AW (1988) Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res 48, 27112714.
  • 156
    Omidfar K, Moinfar Z, Sohi AN, Tavangar SM, Haghpanah V, Heshmat R, Kashanian S & Larijani B (2009) Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies. Immunol Invest 38, 165180.
  • 157
    de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG et al. (2008) The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 99, 341349.
  • 158
    Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN & Butzow R (2006) Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 84, 671681.
  • 159
    Steffensen KD, Waldstrom M, Olsen DA, Corydon T, Lorentzen KA, Knudsen HJ, Jeppesen U, Brandslund I & Jakobsen A (2008) Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. Clin Cancer Res 14, 32783282.
  • 160
    Spindler KL, Olsen DA, Nielsen JN, Brandslund I, Poulsen HS, Villingshoj M & Jakobsen A (2006) Lack of the type III epidermal growth factor receptor mutation in colorectal cancer. Anticancer Res 26, 48894893.
  • 161
    Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C & Modjtahedi H (2005) Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 27, 317325.
  • 162
    Yu H, Gong X, Luo X, Han W, Hong G, Singh B & Tang CK (2008) Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF induced a transient effect on EGFR-mediated signaling pathways. Cancer Biol Ther 7, 18181828.
  • 163
    Tidow N, Boecker A, Schmidt H, Agelopoulos K, Boecker W, Buerger H & Brandt B (2003) Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development. Cancer Res 63, 11721178.
  • 164
    Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Yoshioka M et al. (2003) Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 94, 5056.
  • 165
    Ohtsuka K, Ohnishi H, Fujiwara M, Kishino T, Matsushima S, Furuyashiki G, Takei H, Koshiishi Y, Goya T & Watanabe T (2007) Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer 109, 741750.
  • 166
    Ohtsuka K, Ohnishi H, Furuyashiki G, Nogami H, Koshiishi Y, Ooide A, Matsushima S, Watanabe T & Goya T (2006) Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma. J Thorac Oncol 1, 787795.
  • 167
    Sihto H, Puputti M, Pulli L, Tynninen O, Koskinen W, Aaltonen LM, Tanner M, Bohling T, Visakorpi T, Butzow R et al. (2005) Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. J Mol Med 83, 976983.
  • 168
    Sasaki H, Kawano O, Endo K, Yukiue H, Yano M & Fujii Y (2007) EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncol Rep 17, 319323.
  • 169
    Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK & Huang HS (1996) Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271, 2563925645.
  • 170
    Bowman T, Garcia R, Turkson J & Jove R (2000) STATs in oncogenesis. Oncogene 19, 24742488.
  • 171
    Bromberg JF (2001) Activation of STAT proteins and growth control. BioEssays 23, 161169.
  • 172
    Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B & Bartlett JM (2006) The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 12, 123130.
  • 173
    Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB & Cavenee WK (2002) Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 62, 67646769.
  • 174
    Gottschalk AR, Basila D, Wong M, Dean NM, Brandts CH, Stokoe D & Haas-Kogan DA (2001) p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res 61, 21052111.
  • 175
    Li DM & Sun H (1998) PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95, 1540615411.
  • 176
    Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D & Parsons R (1997) Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57, 41834186.
  • 177
    Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A & Loeffler JS (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22, 19261933.
  • 178
    Klingler-Hoffmann M, Bukczynska P & Tiganis T (2003) Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int J Cancer 105, 331339.
  • 179
    Mendelsohn J & Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19, 65506565.
  • 180
    Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN & Nutt CL (2006) Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65, 11811188.
  • 181
    Wikstrand CJ, McLendon RE, Friedman AH & Bigner DD (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57, 41304140.
  • 182
    Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL & Mischel PS (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63, 27422746.
  • 183
    Sugawa N, Yamamoto K, Ueda S, Morita N, Kita M, Nishino H, Fushiki S & Okabe T (1998) Function of aberrant EGFR in malignant gliomas. Brain Tumor Pathol 15, 5357.
  • 184
    Wu JL, Abe T, Inoue R, Fujiki M & Kobayashi H (2004) IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells. Neurol Res 26, 785791.
  • 185
    Brem S, Tsanaclis AM, Gately S, Gross JL & Herblin WF (1992) Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 70, 26732680.
  • 186
    Giese A, Bjerkvig R, Berens ME & Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21, 16241636.
  • 187
    Platten M, Wick W & Weller M (2001) Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52, 401410.
  • 188
    Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH & Riggins GJ (2002) Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62, 33353339.
  • 189
    Ala-Aho R, Johansson N, Baker AH & Kahari VM (2002) Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. Int J Cancer 97, 283289.
  • 190
    Ntayi C, Lorimier S, Berthier-Vergnes O, Hornebeck W & Bernard P (2001) Cumulative influence of matrix metalloproteinase-1 and -2 in the migration of melanoma cells within three-dimensional type I collagen lattices. Exp Cell Res 270, 110118.
  • 191
    Behrens P, Rothe M, Florin A, Wellmann A & Wernert N (2001) Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med 8, 149154.
  • 192
    Kelly T, Kechelava S, Rozypal TL, West KW & Korourian S (1998) Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. Mod Pathol 11, 855863.
  • 193
    Schmidt MH, Furnari FB, Cavenee WK & Bogler O (2003) Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci USA 100, 65056510.
  • 194
    Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J et al. (2011) Oncogenic EGFR signaling activates an mTORC2-NF-kB pathway that promotes chemotherapy resistance. Cancer Discov 1, 524538.
  • 195
    Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB & Arteaga CL (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22, 28122822.
  • 196
    Chakravarti A, Chakladar A, Delaney MA, Latham DE & Loeffler JS (2002) The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62, 43074315.
  • 197
    Johns TG, McKay MJ, Cvrljevic AN, Gan HK, Taylor C, Xu H, Smyth FE & Scott AM (2010) MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 78, 572578.
  • 198
    Cvrljevic AN, Akhavan D, Wu M, Martinello P, Furnari FB, Johnston AJ, Guo D, Pike L, Cavenee WK, Scott AM et al. (2011) Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. J Cell Sci 124, 29382950.
  • 199
    Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, Tang CK, Hamilton RL, Vuori K, Nishikawa R et al. (2012) Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc Natl Acad Sci USA 109, 30183023.
  • 200
    Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DWY, Cavenee WK & Furnari FB (2012) EGFRvIII promotes glioma angiogenesis and growth through the NF-kB, interleukin-8 pathway. Oncogene 31, 40544066.
  • 201
    Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ & Bigner DD (1997) Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324 (Pt 3), 855861.
  • 202
    Zhang X, Gureasko J, Shen K, Cole PA & Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 11371149.
  • 203
    Ymer SI, Greenall SA, Cvrljevic A, Cao DX, Donoghue JF, Epa VC, Scott AM, Adams TE & Johns TG (2011) Glioma specific extracellular missense mutations in the first cysteine rich region of epidermal growth factor receptor (EGFR) initiate ligand independent activation. Cancers 3, 20322049.
  • 204
    Hwang Y, Chumbalkar V, Latha K & Bogler O (2011) Forced dimerization increases the activity of DeltaEGFR/EGFRvIII and enhances its oncogenicity. Mol Cancer Res 9, 11991208.
  • 205
    Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB & White FM (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104, 1286712872.
  • 206
    Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, Yao J, Priebe W, Colman H, Elferink LA et al. (2013) Regulation of HGF expression by DeltaEGFR-mediated c-Met activation in glioblastoma cells. Neoplasia 15, 7384.
  • 207
    Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P et al. (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24, 17311745.
  • 208
    Furnari F, Inda MD, Bonavia R, Sah D, Mukasa A, Narita Y, Johns TG, Bachoo R, Hadwiger P, Tan P et al. (2009) Tumor heterogeneity in glioblastoma is actively maintained by a paracrine circuit driven by mutant EGFR. Neurooncology 11, 566566.
  • 209
    Swinnen JV, Brusselmans K & Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9, 358365.
  • 210
    Warburg O (1956) On the origin of cancer cells. Science 123, 309314.
  • 211
    Gleason CE, Lu D, Witters LA, Newgard CB & Birnbaum MJ (2007) The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J Biol Chem 282, 1034110351.
  • 212
    Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE & Shaw RJ (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30, 214226.
  • 213
    Choi BD, Kuan C-T, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD & Sampson JH (2013) Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci USA 110, 270275.
  • 214
    Gan HK, Lappas M, Cao DX, Cvrljevdic A, Scott AM & Johns TG (2009) Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. J Cell Mol Med 13, 39934001.
  • 215
    Gajadhar AS, Bogdanovic E, Munoz DM & Guha A (2012) In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Mol Cancer Res 10, 428440.
  • 216
    Dreier A, Barth S, Goswami A & Weis J (2012) Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance? Tumour Biol 33, 8594.
  • 217
    Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF et al. (2007) Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest 117, 346352.
  • 218
    Jutten B, Dubois L, Li Y, Aerts H, Wouters BG, Lambin P, Theys J & Lammering G (2009) Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells. Radiother Oncol 92, 393398.
  • 219
    Haas-Kogan D, Prados M, Tihan T, Eberhard D, Jelluma N, Arvold N, Baumber R, Lamborn K, Kapadia A, Malec M et al. (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97, 880887.
  • 220
    Gan HK, Burgess AW, Clayton AHA & Scott AM (2012) Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 72, 29242930.
  • 221
    Cleary JM, Yee LK-C, Azad N, Carducci M, Cosgrove D, Limaye S, Gandhi L, Pedersen M, Ansell P, Ames W et al. (2012) A phase 1 study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors. In Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, 31 March to 4 April 2012, Chicago, IL, Abstract 2506. AACR, Philadelphia, PA.
  • 222
    Scott AM, Lee F-T, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B et al. (2007) A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 104, 40714076.
  • 223
    Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE II, McLendon RE, Mitchell DA et al. (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28, 47224729.
  • 224
    Torp SH, Gulati S, Johannessen E & Dalen A (2007) Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res 26, 353359.
  • 225
    Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WKA, Colman H et al. (2007) Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25, 22882294.
  • 226
    Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB et al. (2008) Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26, 56035609.
  • 227
    Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M et al. (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27, 579584.
  • 228
    Liu L, Backlund LM, Nilsson BR, Grander D, Ichimura K, Goike HM & Collins VP (2005) Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83, 917926.
  • 229
    McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH & Bigner DD (2000) Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 48, 11031110.
  • 230
    Silva HA, Abraul E, Raimundo D, Dias MF, Marques C, Guerra C, de Oliveira CF & Regateiro FJ (2006) Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients. Eur J Cancer 42, 26172622.
  • 231
    Tawbi H, Thomas D, Lucas DR, Biermann JS, Schuetze SM, Hart AL, Chugh R & Baker LH (2008) Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist 13, 459466.
  • 232
    Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, Neale G, Dome JS, Daw NC & Khoury JD (2008) Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 113, 14531461.